Oncology Newswire

Oncology Newswire

Comprehensive Real-Time News Feed for Oncology.

Results 1 - 20 of 30,537 in Oncology

  1. Cerulean Pharma Inc (CERU) to Post FY2016 Earnings of ($2.08) Per Share, Leerink Partner ForecastsRead the original story w/Photo

    18 min ago | AmericanBankingNews.com

    ... the quarter, missing analysts' consensus estimates of ($0.43) by $0.06. Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform ...

    Comment?

  2. Biking saved my life -literallyRead the original story w/Photo

    47 min ago | Washington Blade

    In my early 20s, I rode my bike everywhere. I rode in the pea soup heat that is D.C. in August.

    Comment?

  3. Mirati Therapeutics Reports Financial Results And Business Update For The First Quarter 2016Read the original story

    1 hr ago | Freshnews

    Mirati Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2016 and provided an update on its product development programs. "We are encouraged by the progress made so far this year in advancing our three clinical stage oncology drug candidates, which we believe hold significant promise for patients with lung cancer and other serious forms of cancer," said Charles M. Baum, M.D., Ph.D., President and CEO of Mirati.

    Comment?

  4. Malignant Mesothelioma Market - Latest Innovations, Drivers,...Read the original story w/Photo

    1 hr ago | SBWire

    ... the basis of end user, global market for malignant mesothelioma is segmented into: Hospital Cancer Research Centers Oncology Hospitals Interested in report: Please follow the below the links to meet your requirements; Request for the Report ...

    Comment?

  5. Understanding the Drug Developer's Perception of ValueRead the original story w/Photo

    1 hr ago | The American Journal of Managed Care

    ... That is a way to reduce costs. Bruce A. Feinberg, DO, and Ira Klein, MD, MBA, FACP, discuss treatment innovation in oncology. When determining the effectiveness of one option versus another in a growing market, Dr Klein suggests that new measures ...

    Comment?

  6. Arguing for the Patient as the Consumer of HealthcareRead the original story w/Photo

    1 hr ago | The American Journal of Managed Care

    Bruce A. Feinberg, DO: I think an argument could be made that the patient is the recipient of care, but they're not the consumer of care. In fact, from a medical oncologist perspective from someone who has practiced medical oncology for 25 years, my referring doctors were consumers.

    Comment?

  7. Medivation Reports First Quarter 2016 Financial ResultsRead the original story

    1 hr ago | Freshnews

    ... vs. prior year). "Medivation is off to a strong start in 2016 as we continue to expand our leadership position in oncology, extend XTANDI's reach into urology and other areas, and advance our robust late-stage pipeline," said David Hung, M.D., ...

    Comment?

  8. Clovis Oncology Announces Q1 2016 Operating Results and Corporate UpdateRead the original story

    1 hr ago | Freshnews

    Clovis Oncology , Inc. reported financial results for its quarter ended March 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of 2016. "We are very disappointed in the outcome for rociletinib, as there is a need for additional options for this difficult to treat disease," said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

    Comment?

  9. Progenics Pharmaceuticals, Inc. (PGNX) Stock Price Down 3.5% Following Weak EarningsRead the original story w/Photo

    1 hr ago | AmericanBankingNews.com

    ... $4.73 and a 200 day moving average of $5.41. Progenics Pharmaceuticals, Incis engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II ...

    Comment?

  10. Progenics Pharmaceuticals, Inc. (PGNX) Issues Quarterly Earnings...Read the original story w/Photo

    1 hr ago | AmericanBankingNews.com

    ... "Buy" and an average price target of $10.35. Progenics Pharmaceuticals, Incis engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II ...

    Comment?

  11. Prostate Cancer Screening Guidelines Raise Men's Risks: DocsRead the original story w/Photo

    1 hr ago | News Max

    ... Robotic Surgery at New York-Presbyterian/Weill Cornell Medical Center and the Ronald Lynch Professor of Urologic Oncology at Weill Cornell Medicine. "While there are risks of over-diagnosis and over-treatment associated with PSA testing, it can play ...

    Comment?

  12. Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer releasedRead the original story w/Photo

    2 hrs ago | PhysOrg Weblog

    ... change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, ... The International Association for the Study of Lung ...

    Comment?

  13. MacroGenics Inc (MGNX) Upgraded by Zacks Investment Research to HoldRead the original story w/Photo

    2 hrs ago | Daily Political

    ... therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " Shares of MacroGenics ( ...

    Comment?

  14. Q2 2016 EPS Estimates for Cerulean Pharma Inc (CERU) Reduced by WedbushRead the original story w/Photo

    2 hrs ago | Daily Political

    ... missing the Thomson Reuters' consensus estimate of ($0.43) by $0.06. Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform ...

    Comment?

  15. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Receives Average Rating of...Read the original story w/Photo

    2 hrs ago | AmericanBankingNews.com

    ... Pharmaceuticals worth $609,000 as of its most recent filing with the SEC. ARIAD Pharmaceuticals, Inc is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the ...

    Comment?

  16. Medivation Reiterates Rejection of Sanofi's Unsolicited BidRead the original story

    2 hrs ago | The Washington Post

    ... San Francisco-based company, which has one marketed medicine for prostate cancer, Xtandi, and is developing other oncology treatments, said the Sanofi proposal would deny its stockholders the value of future products. Meanwhile several other suitors ...

    Comment?

  17. Drug to benefit women at higher risk of developing breast cancerRead the original story

    3 hrs ago | Central Western Daily

    WOMEN at higher risk of developing breast cancer who are prescribed the drug Tamoxifen are now able to access the drug under the Pharmaceutical Benefits Scheme . WOMEN at higher risk of developing breast cancer who are prescribed the drug Tamoxifen are now able to access the drug under the Pharmaceutical Benefits Scheme .

    Comment?

  18. Law firm donation helps cancer patientsRead the original story w/Photo

    3 hrs ago | Cotswold Journal

    ... Run jointly by the charity and the Gloucestershire Hospitals NHS Foundation Trust, it is based at Cheltenham Oncology Unit and travels to the Forest of Dean, Tewkesbury, Stroud and Cirencester each week. Charity Founder Christine Mills said: "All of ...

    Comment?

  19. Life-line for some with melanomaRead the original story

    3 hrs ago | The Otago Daily Times

    Some Dunedin melanoma patients died after they could not access a life-extending cancer drug that looks set to be funded in a couple of months, Dunedin oncologist Chris Jackson says. The public debate over the Keytruda drug put pressure on the Government, and this week it announced Pharmac will receive $39million extra funding in 2016-17 from this month's Budget.

    Comment?

  20. Study Points to Therapeutic Target for Common and Aggressive Ovarian CancerRead the original story

    5 hrs ago | Newswise

    ... Ram, Ph.D., and Yiling Lu, M.D., all of Systems Biology; Sunila Pradeep, Ph.D. and Anil Sood, M.D., Gynecologic Oncology; Andreia Machado Silva, Cristian Rodriguez-Aguayo, Ph.D., Gabriel Lopez-Berestein, M.D. and George Calin, M.D., Ph.D., ...

    Comment?